Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus TRIMPEX 200.
COR-OTICIN vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
1-2 drops in each affected ear twice daily for 7 days.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic